Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1985 3
1993 1
2003 1
2004 2
2006 2
2007 2
2008 1
2009 3
2010 4
2011 4
2012 8
2013 7
2014 7
2015 4
2016 4
2017 3
2018 5
2019 2
2020 5
2021 2
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN–PE Investigators, et al. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22449293 Free article. Clinical Trial.
Contract Law in Common Law Countries: A Study in Divergence.
Kumar M, Heidemann M. Kumar M, et al. Among authors: heidemann m. Liverp Law Rev. 2022;43(2):133-147. doi: 10.1007/s10991-022-09312-8. Epub 2022 Jul 14. Liverp Law Rev. 2022. PMID: 35855297 Free PMC article. No abstract available.
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial.
Eklöf J, Alispahic IA, Sivapalan P, Wilcke T, Seersholm N, Armbruster K, Kjærgaard JL, Saeed MI, Nielsen TL, Browatzki A, Overgaard RH, Fenlev CS, Harboe ZB, Andreassen HF, Lapperre TS, Pedersen L, Johnsen S, Ulrik CS, Janner J, Moberg M, Heidemann M, Weinreich UM, Vijdea R, Linde H, Titlestad I, Johansson SL, Rosenvinge FS, Østergaard C, Ghathian KSA, Gundersen L, Christensen CW, Bangsborg J, Jensen TT, Sørensen VM, Ellingsgaard T, Datcu R, Coia JE, Bodtger U, Jensen JUS. Eklöf J, et al. Among authors: heidemann m. Trials. 2022 Sep 27;23(1):817. doi: 10.1186/s13063-022-06720-z. Trials. 2022. PMID: 36167555 Free PMC article. Clinical Trial.
Molecular evolution of the RNA polymerase II CTD.
Chapman RD, Heidemann M, Hintermair C, Eick D. Chapman RD, et al. Among authors: heidemann m. Trends Genet. 2008 Jun;24(6):289-96. doi: 10.1016/j.tig.2008.03.010. Epub 2008 May 9. Trends Genet. 2008. PMID: 18472177 Review.
Chemical-genomic dissection of the CTD code.
Tietjen JR, Zhang DW, Rodríguez-Molina JB, White BE, Akhtar MS, Heidemann M, Li X, Chapman RD, Shokat K, Keles S, Eick D, Ansari AZ. Tietjen JR, et al. Among authors: heidemann m. Nat Struct Mol Biol. 2010 Sep;17(9):1154-61. doi: 10.1038/nsmb.1900. Epub 2010 Aug 29. Nat Struct Mol Biol. 2010. PMID: 20802488 Free PMC article.
71 results